Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
Oncotarget|November 18, 2015
INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomasMeng Na Chi, Su Tang Guo, James S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2021
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in MelanomaGregory M Kelly, Fares Al-Ejeh, Robert McCuaig, et al.
Nature Communications|April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanomaXinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK InhibitorsHojabr Kakavand, Robert V Rawson, Gulietta M Pupo, et al.
JCO Precision Oncology|March 12, 2026
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL StudyAndrea Boutros, Matteo S Carlino, Raja Chaganti, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Oncotarget|October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cellsSelina K Sutton, Jessica Koach, Owen Tan, et al.
The Journal of Investigative Dermatology|August 31, 2012
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanomaGraham J Mann, Gulietta M Pupo, Anna E Campain, et al.
Ebiomedicine|July 10, 2022
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithmsThazin Nwe Aung, Saba Shafi, James S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentJarem Edwards, James S Wilmott, Jason Madore, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Oncotarget|November 18, 2015
INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomasMeng Na Chi, Su Tang Guo, James S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2021
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in MelanomaGregory M Kelly, Fares Al-Ejeh, Robert McCuaig, et al.
Nature Communications|April 8, 2024
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanomaXinyu Bai, Grace H Attrill, Tuba N Gide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK InhibitorsHojabr Kakavand, Robert V Rawson, Gulietta M Pupo, et al.
JCO Precision Oncology|March 12, 2026
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL StudyAndrea Boutros, Matteo S Carlino, Raja Chaganti, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Oncotarget|October 22, 2014
TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cellsSelina K Sutton, Jessica Koach, Owen Tan, et al.
The Journal of Investigative Dermatology|August 31, 2012
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanomaGraham J Mann, Gulietta M Pupo, Anna E Campain, et al.
Ebiomedicine|July 10, 2022
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithmsThazin Nwe Aung, Saba Shafi, James S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 TreatmentJarem Edwards, James S Wilmott, Jason Madore, et al.
Pageof 17